Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424434 | 0.78 | TGM2 (0.64) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL59151 | 0.78 | KEAP1 (0.64) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL6005110 | 0.78 | CA2 (0.64) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL11335118 | 0.77 | TGM2 (0.61) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL23141160 | 0.76 | KEAP1 (0.61) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL27952528 | 0.75 | KEAP1 (0.54) | KEAP1CA2CA1IL1RNERAP1 | |
| Formaldehyde SCHEMBL28212330 | 0.75 | CA2 (0.54) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL1706481 | 0.75 | CA1 (0.61) | CA2CA1KMT2AMEN1ALDH1A1 | |
| SCHEMBL7438763 | 0.75 | CA1 (0.61) | CA2CA1KMT2AMEN1ALDH1A1 | |
| SCHEMBL5378696 | 0.74 | CA2 (0.58) | KEAP1CA2CA1IL1RNERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819667-B1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-6384028-B1 | TREATMENT OF CARDIOVASCULAR DISORDERS, ANTICOAGULANTS AND VALVE REPLACEMENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | KEAP1 4038/4885CA2 1729/4885CA1 1175/4885 |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | KEAP1 1162/4885CA2 413/4885CA1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.